Geron Corporation

Good afternoon. My name is Rob and I will be your conference operator today. At this time, I would like to welcome everyone to the Geron Earnings second quarter 2022 conference call. All lines have been placed on mute to prevent any background noise. And today's conference is being recorded. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again press star one. Thank you. Erin Feingold, Vice President of Investor Relations and Corporate Communications. You may now begin your conference.

Good afternoon, everyone. Welcome to the Geron Corporation second quarter 2022 conference call. I am Erin Feingold, Geron's Vice President of Investor Relations and Corporate Communications. I'm joined today by the following members of Geron's management team. Dr. John Scarlett, Chairman and Chief Executive Officer. Olivia Bloom, Executive Vice President of Finance and Chief Financial Officer and Treasurer. Dr. Fay Feller, Executive Vice President and Chief Medical Officer. And Anil Kapoor, Executive Vice President of Corporate Strategy and Chief Commercial Officer. Before we begin, please note that during the course of this presentation and question and answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those relating to the therapeutic potential and potential regulatory approval of Immatel-Stat, anticipated clinical and commercial events, and related timelines. the sufficiency of Jerron's financial resources, and other statements that are not historical fact. Actual events or results could differ materially. Therefore, I refer you to the discussion under the heading Risk Factors in Jerron's quarterly report on Form 10-Q for the quarter ended June 30, 2022, which identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statements. Jaron undertakes no duty or obligation to update our forward-looking statement. And now, I will turn the call over to CEO Dr. Scarlett. Chip?

Thanks, Erin. Good afternoon, everyone. Thanks for joining us today. This is an exciting time to be at Jaron. We expect the journey ahead will emphasize potential value-accreting milestones that reflect InnoTelStats' unique and highly differentiated qualities that in turn we believe address many of the current unmet needs of patients with both lower risk myelodysplastic syndromes, or MDS, and refractory myelofibrosis, or MF. As such, we're planning for an upcoming catalyst-rich period during which we will be focused intently on the execution that we expect will take us from being a development stage company to a commercial company. I'm personally very excited that we're only five months away from the first of these exciting milestones, which is the disclosure of top line results from our Emerge Phase 3 trial in lower risk MDS that are expected in early January of 2023. In advance of those top line results, we're already actively preparing for two regulatory submissions in the syndication lower risk MDS. The first, expected in the first half of 2023, will be a submission of a U.S. new drug application, NDA, and the second, which will be the submission of a European marketing authorization application, or MAA, which we expect in the second half of 2023. If the lower-risk MDS top-line results are positive and these regulatory activities are successful, we expect U.S. approval and commercial launch of Imatelstat and lower-risk MDS in the first half of 2024. Also in 2024, we anticipate an interim analysis of the ongoing IMPACT-MF phase three study in refractory myelofibrosis. This assumes that enrollment meets our expectations and that a sufficient number of events have occurred to enable such an analysis. A positive readout in this trial, which is comparing Imatelstat to best available therapy, would have major implications. Impact MS is the only MS study being conducted today with a primary endpoint of overall survival. Improvement in overall survival is consistently ranked by hematologists near or at the top of the desired qualities of a new medicine in refractory MS. Returning to lower risk MDS, we believe Imatelstat represents a potentially transformative treatment option as well as a significant commercial opportunity in this indication. Based on the market research conducted by our commercial team, practicing hematologists cite several key attributes of imitelstat that were observed in the eMERGE Phase II study and that address current unmet medical needs in this indication. First, the durability of transfusion independence that was observed in Phase II addressed what these hematologists cited as the most significant current unmet need for the lower risk MDS patients. Second, they cited the expected ability of Imatelstat to treat a broader set of patients, including both RS-positive and RS-negative subsets, as well as a broad range of patients with high and very high transfusion burdens. They believe data such as these would differentiate Imatelstat significantly from other currently available therapies in this indication. For example, Luspatercept is restricted for use in only RS-positive patients, which represents approximately a quarter of the market. Third, these hematologists cited the novel mechanism of action of Imatelstat. This mechanism is also significantly differentiated from the mechanism of other treatments for low-risk MDS and leads to the potential for disease modification. This disease-modifying potential was supported by clinical outcomes in the Phase II study including very meaningful increases in hemoglobin, as well as depletion of malignantly transformed cells after treatment with imetel statin. These key attributes, as well as a manageable safety profile from the Phase 2 study, give us confidence that the outcomes in the Phase 3 trial have the potential to address the unmet needs of the approximately 33,000 patients with lower risk MDS in the US and largest five EU markets who are relapsed and refractory to ESAs. This translates to a significant market opportunity of approximately $1.2 billion in potential peak revenues across these lower risk MDS markets. To capitalize on the potential of this market opportunity, a stage-gated build-out of the US commercial team and plan has begun. which we plan to accelerate if we achieve positive top-line results in early January 2023. For Europe, we're considering our options, including potential partners, as well as self-commercialization, with the goal of bringing Imatelstat to patients in that marketplace as efficiently and effectively as possible. Putting these upcoming milestones together, we believe Geron has the necessary elements for significant value creation over the next several years. These include the lower risk MDS phase three top line data, the build out of the U.S. commercial team and plan, the impact MF phase three data from the interim analysis, and the unique product attributes of Immetelstat that are expected to allow it to successfully address unmet needs. In addition to the corporate attributes I've already discussed, another key element that we expect to lead to an ability to deliver the expected value creation is our strong balance sheet. In late March of this year, we raised approximately $70 million in net proceeds from a public follow-on offer. This past quarter, we secured up to an additional $50 million in potential non-deleted capital through an amendment to expand our existing loan facility with Hercules Capital and Silicon Valley Bank. These additional debt tranches increase our total available debt facility from up to $75 million to up to $125 million. We believe these potential additional debt proceeds when added to our current financial resources and the projected proceeds from exercises of current outstanding warrants in 2023 will be sufficient to fund our projected level of operations until the middle of 2024. This strong balance sheet should also give us flexibility as we consider potential additional strategic funding and partnership opportunities after disclosure of top-line results in the lower-risk MDS Phase III trial in early January of 2023. Finally, I'd like to comment on our deeply talented management team. We continue to build an employee base that is both experienced and knowledgeable in hematologic malignancies, as well as in the commercial path ahead. The recent appointment of Dr. Faye Fowler as our Chief Medical Officer, with Dr. Alexandra Rizzo having transitioned to her new role as Senior Medical and Regulatory Advisor, exemplifies the type of management expertise and capabilities in Jurong today. Faye has been a cornerstone in the history of Immatel-Statt's clinical development, from working on the Phase II Immatel-Statt studies at Janssen starting in 2015, to driving our Phase III trials and designing our pipeline expansion studies at Jurong, beginning in 2019, Faye has been instrumental in the design and management of the entire Immatel-Statt development program in malignancies. I'd like to give Faye the opportunity to briefly introduce herself on this call. Following that, Olivia will provide a financial update, and then I'll make my concluding remarks. Faye?

Thank you, Chip, for the kind introduction. I'm delighted to be speaking to all of you today and to be settling into my new role. I've been very lucky to be involved in the Immateltat journey for the past seven years, beginning at Janssen and then since 2019 at Geron. It is an incredible honor to lead a clinical development effort as chief medical officer as we plan to read out two pivotal trials for Immateltat over the next two years. By way of a personal introduction, I'm a hematologist and medical oncologist trained at Mount Sinai and Memorial Sloan Kettering Cancer Center. I subsequently joined the faculty at Memorial as an attending physician on the leukemia service before joining Janssen. At Janssen, I was a study physician for multiple clinical trials of early and late stage development assets, including the Embark Phase II clinical trial of Imatelstat, as well as other product candidates, including several in AML. Since coming to Geron in 2019, I've been the primary medical point of contact with our clinical investigators, and involved in all parts of running the phase three trials and designing the pipeline expansion studies. With that, I'll turn the call over to Olivia for a financial update. Olivia.

Thanks, Faye, and thanks to everyone on the call for joining us today. Please refer to the press release we issued this afternoon, which is available on our website for detailed financial results. As of June 30, 2022, we had approximately $220 million in cash and marketable securities, which includes net proceeds of approximately $70 million from the underwritten public offering we completed in April of this year. Overall, operating expenses were slightly lower for the three and six months ended June 30, 2022, compared to the prior period. This overall decline primarily reflects changes in the composition of activities from last year. For example, the decrease in R&D expenses for the three- and six-month periods of 2022 compared to the same period in 2021 primarily reflects the net result of decreased manufacturing costs due to the timing of Ematelstat manufacturing batches, partially offset by increased personnel-related expenses for additional headcount. and higher consulting costs related to preparation for top line results and regulatory submissions in lower risk MDS. The decline in general and administrative expenses for the six months ended June 30, 2022, compared to the same period in 2021, primarily reflects the net results of reduced consulting costs related to modernizing the internal infrastructure to support potential commercial launch and lower legal fees, partially offset by higher personnel related expenses for additional headcount. We continue to expect non-GAAP total operating expenses up to $150 million for the full year of 2022. Under current planning assumptions, we expect to have approximately $130 million in cash and marketable security at the time of the lower risk MDS top line results in early 2023. As Chip mentioned, in late June, we amended our existing loan facility with Hercules Capital and Silicon Valley Bank to expand the facility from up to $75 million to up to $125 million. This expansion of our debt facility provides potential access of up to $50 million in additional non-dilutive capital in 2023, which is the year in which we expect lower-risk MDS top-line results, and if the data are supportive, U.S. and EU regulatory filings thereafter. We also project up to $124 million in additional funding in 2023 from potential exercises of currently outstanding warrants. We believe the additional $50 million from potential additional debt proceeds, when added to the projected exercise proceeds from outstanding warrants and our current financial resources, will be sufficient to fund our projected level of operations, which includes stage-gated activities for potential U.S. commercial launch of Emitel's debt in low-risk MDS, until the middle of 2024. With that, I will now turn the call over to Chip for closing remarks.

Thanks, Olivia. Well, I'd like to end where I began, emphasizing what an exciting and important time this is for Gerard. We expect Imatelstat's highly differentiated attributes to address many of the significant unmet needs of patients with both lower-risk MDS and refractory IMAP. As you've heard several times today, we're eagerly anticipating a Phase III lower-risk MDS readout in early January of 2023. We also believe that MattelStat has potential multi-billion dollar market opportunities. And supporting these efforts, as Olivia just described, is a well-funded balance sheet that currently takes us into mid 2024. I and my colleagues believe this set of circumstances has the potential to transform Geron into a leader in the treatment of hematologic malignancies and to bring significant value to patients and shareholders. Thank you very much for listening today. Operator, please open the call to questions.

At this time, I would like to remind everyone, in order to ask a question, press star, then the number one on your telephone keypad. Your first question comes from the line of Kalpit Patel from B. Reilly Securities. Your line is open.

Yeah, hey, good morning. Hi, Kalpit. Thanks for... Good morning. Hey, good morning. Good afternoon. Thanks for taking the questions. I guess first, you know, starting with the lower risk MDS program, as you sort of get closer to the final stages and assuming that trial reads out positive, how are you thinking about the potential utilization in the real world? You touched on, you know, you touched on this in the prepared remarks for the RS positive and RS negative patients. But would you think the drug would be more likely to be reserved for patients who have a greater transfusion burden and perhaps those who are unlikely to use luspatasap? Just any more color on that would be useful.

Thanks a lot. I think this would best be taken first by Anil Kapoor, our chief commercial officer. He'll have a few comments. Thanks.

Sure, Kalpat. Thank you for the question. So, Kalpat, as you know, we are addressing a very high unmet medical need in patients who are transfusion-dependent post-TSAs. These patients have shortened survival, and they suffer from very poor quality of life. Despite new advances, some of which you mentioned, what we are clearly seeing in our research and our discussions with clinicians and from scientific and clinical forums is significant dissatisfaction with current options especially as it relates to durability of transfusion independence and ability to address the need of high transfusion burden patient populations in this market vast majority of the patients have they come with high transfusion burden our data with the phase 2 study shows unprecedented durability of ti We have guided in the past that we expect to present 24-week transfusion independence data, which has been regarded as one of the most important clinical outcomes by physicians. So we expect commercially imital start to be very well differentiated, positioned as a standard of care across both RS positive and RS negative. And with our unique mechanism of action, our ability to kill the malignant stem cell and potential for disease modification, I think it is set up for big success. We do not comment on competitor products and their adoption, but what is very clear is the durability of TI in the real world remains a high unmet medical need, and it is regularly cited by practicing hematologists across both indications. So I'll just stop here.

Okay. That's very helpful. And then maybe one on the relapse refractory myelofibrosis program. The Phase II data, you know, in the past have suggested improved survival with imitalistat when compared to historical controls. I guess, has anything changed in terms of the best available therapy in this relapsed refractory setting from the days of the historical controls to what's being used today? I'm just trying to delineate if we should expect any changes in that comparator arm relative to what we have seen historically. Thank you.

Right. Uh, thanks Cal, but I'll take that one. Uh, it's pretty straightforward. So as you know, we did not only, um, the, uh, not only the phase two study, um, the embarked phase two study, but we also did a real world data study in which we, um, did a, uh, careful matching with patients at the Moffitt who, uh, were relapsed and refractory to Jack inhibitors. And in that, um, in that exercise, in that sort of synthetic study, we actually looked very carefully at the BAT, at the best available therapy that would be available. And I think that since our study does exclude JAK inhibitors in the BAT arm, I don't think we expect to see very much difference. In fact, we've commented a couple of times publicly that we expect the BAT arm in the Phase III impact MF study to be very similar to what we saw in the real world data study for using the Moffitt patients.

Okay, that's very helpful. And if I could squeeze in one more for sure, improve MF, the phase one study in combo with RUX. I guess, how is the enrollment going for that trial that started in May? Can you comment on any pushback that you might be receiving from

investigators or any general thoughts on you know the additive profile of maybe additive adverse event profile of the two drugs that's a great question so i'm gonna um i'll take just the first part which is super simple uh way early days we we really just got going on this so uh probably premature to comment about the pace of enrollment but say maybe you want to talk about the question of how investigators are sort of looking at this and how they're thinking about the potential combination of Rux and Imatelstat in Frontline.

Sure. Thanks, Chip. Thanks for the question. So today we've opened two of the three sites, and we continue to receive positive feedback from investigators on combination therapy. The field is headed towards combination therapy, and we're...

we remain confident. Okay. Thank you very much. Thanks for taking the question. You bet. Thank you, Calvin.

Your next question comes from a line of Joel Beattie from Baird. Your line is open.

Hi. Thanks for taking the question. The first one's on the emergency phase three trial in MDS. Are you able to share how, you know, the dropout rate or dose reduction or different measures like that are looking compared to expectations?

So, Joel, we, first of all, number one, we remain blinded to the study. Number two, we're, you know, in pharmaceutical development terms, we're pretty much there, and we'll see the results soon enough. So, we would not be making any comments about the conduct of that study or any, you know, sort of interim looks or anything like that. We haven't done them. So I'm afraid we'll have to wait to see all of that sort of data come out in early January.

Okay, sure. Yeah, it makes sense. And certainly it's coming soon, though. All right. So assuming the trial is successful, what would the filing timeline be? You know, are you able to narrow it down to what part in 2023? And then beyond the trial results from eMERGE, what else remains to be done before filing?

Sure, we can give you a little bit of color on that. We said that we expect the filing to be or the submission, I guess I should say, specifically to be made in the first half of 2023. As you know, there's a couple of months to go by usually while the FDA looks at that and then they officially file it. But we've simply given guidance that we expect the filing in the first half. There's been a ton of activity as you would expect. There are many modules to an NDA, the only one of which really relies on the final data from the phase three in this case. So all of the preclinical has been worked on extensively, the CMC, the quality modules. So I think I would, and pretty much everything. So I think I would say we have a very good head start on it all. And that's why we can give that kind of comfort in terms of filing or, sorry, submitting the NDA.

So I think we feel very good about that. Great. Thank you. Sure.

And your next question comes from the line of Steven Wiley from Stifel. Your line is open.

Yeah. Good afternoon. Thanks for taking the questions. On the BD front, I know you mentioned wanting to maybe explore partnership opportunities on the back of iMERGE data. Can you say if you've had any kind of preliminary discussions with any strategics thus far, and is it safe to assume that any deal would also have to contemplate the option of the Metallostat within MF as well?

So, let me take the latter part first. I think that it would be extremely difficult and probably practically impossible to split indications here. I mean, 98, 99% of the time, as we all know, indications don't get split in any type of partnership opportunity. But in this case, because many of the investigators or many of the treating physicians are the same, et cetera, it's, you know, they're kind of kissing cousin diseases. not only biologically, but also from a practice perspective, I think would be pretty, pretty impossible. So I think you can assume that it's everything would would involve both indications, and we see them both as huge value drivers. The second question, you know, I can't really comment on. Obviously, we have a, you know, we hired Ed Cavallos, our chief business officer at the end of last year. You can certainly imagine that he and others are busy. But I think beyond that, it would be not appropriate for us to make any comments. We remain, except to say that we remain very committed to seeing this product on the market, Steve. We believe it brings huge benefit to patients. It obviously is a key value driver for us. So when we look at all the different options that I suspect will be available, or at least some of Some will be available after the turn of the cards in the beginning of next year. I think we'll keep that in mind. And we are building out a very robust commercial group and fully expect to be prepared to launch that product on time whenever we have the opportunity and do so enthusiastically. So I don't know. Anil, is there anything else we should say about that? Or is that adequate from your perspective?

adequate from my perspective. Nothing more to add on that.

Okay. All right. Thanks.

And then just to follow up, so the telomere study, which is, I guess, the investigator-sponsored study of relapsed refractory AML, can you tell us what the starting dose of imetelstat will be in that study, specifically in combination with venetoclax and I'm just curious how you think those two drugs will get along, considering some of the overlap on the heme toxide.

Yeah, I'm going to turn that over to Faye, but just to be crystal clear, telomere itself is in AML, right? And as you quite rightly pointed out, it's in post-ASA or post-venetoclax-treated relapsed refractory ML patients. But I think that's what you were asking about.

So it's in post venetoclax?

Yeah, so Faye can explain the design of telomere.

Thanks, Chip, and thanks for the question. So telomere is in relapsed refractory AML, and patients can have had exposure to venetoclax or HMA previously, or they may not have. or either of them. So in terms of the dose, I don't believe we've released that publicly before, so I cannot comment on it.

Okay. So it's a single agent. Yeah, but we can, yeah. But just so we can be crystal clear, it's in AML. And, Faye, it's also, so it's in combination, there are sort of two parts to it, right? It's in combination with Vinoclax. Or it's in combination with azacitidine?

One arm is in combination imatelstat and venetoclax, and another arm is combination imatelstat and azacitidine. Right.

Okay, if that helps, Steve. Thanks.

And again, if you would like to ask a question, press star, then the number one on your telephone keypad. Your next question comes from the line of Stephen Wiley. I'm sorry, from Gil Blum from Needham & Company. Your line is open.

Hi, everyone, and thank you for taking our singular question. A bit of a follow-up on that earlier Lusperacept angle. Maybe I'll attack it from a different direction. So it looks like Lusperacept is expected to reach a blockbuster status by 2023, and this is despite it being restricted by our statistics. Do you think this suggests potential for more impressive penetration just based on reduction of transfusion burden? I mean, it kind of suggests that there's a very large unmet population there, right?

Anil, I think this is in your purview.

So, Jill, what I can – I don't know what blockbuster status means. Obviously, it's a really – important advance in low-risk MDS, a disease which saw really no innovation come through for almost a decade. These patients, as I previously highlighted, especially patients who are ESA relapsed refractory, they come with significant transfusion burden. What the marketplace is seeing in terms of adoption is the realization of that unmet need. But now that that drug is on the market for some time, we are also seeing real world utilization patterns and the real story emerge around these drugs. And that's why, as I previously stated, durability of transfusion independence becomes a really, really important metric for these patients to address high unmet medical need. We are seeing up-dosing phenomenon among competitor drugs as they are searching for responses. Our expectation is that given the fact that we are mechanistically different, the data set that we bring out is highly differentiated. It is going to showcase and really meet the unmet need across both these populations with the breadth and durability. And to your question around high transfusion burden, number of patients. I think you're absolutely right. The ESA literature for the last two decades has been very clear. Patients three plus are literally 60, 70% of the presenting population. So we are going to bring out data which is highly relevant to the community and patients really deserve these options. So I'll just stop here, Gil, if I answered all your questions. And if you have a follow-up, I'll try to answer that as well.

That was very helpful. And yes, I think that's a good summary of the items.

Thank you. Thank you.

And there are no further questions at this time. Ms. Erin Feingold, I turn the call back over to you for some final closing remarks.

Thanks so much to everyone for joining us today. We appreciate you taking the time to dial into our call. We look forward to keeping you up to date on our progress and hope that you are all well. Thanks so much.

This concludes today's conference call. Thank you for your participation. You may now disconnect.